RedShiftBio at the 2024 National Biotechnology Conference

As the biopharmaceutical industry continues to advance at an unprecedented pace, staying at the forefront of innovation is imperative for companies seeking to develop and optimize novel therapeutics. As a leading provider of high-resolution analytical instrumentation, RedShiftBio is poised to demonstrate our groundbreaking solutions at the upcoming AAPS National Biotechnology Conference in San Francisco, CA.

Visit RedShiftBio at Booth 313 to explore our latest developments in the discovery and development of biologics and new modalities. With a focus on addressing the challenges associated with preformulation and formulation development, Aurora, powered by Microfluidic Modulation Spectroscopy (MMS), offers unparalleled insights into the structural characteristics of complex biomolecules like RNA, proteins, peptides and beyond.

In an era marked by the emergence of diverse therapeutic modalities such as oligonucleotides, as well as the evolving landscape of traditional therapeutics like monoclonal antibodies and antibody-drug conjugates, the need for advanced analytical platforms has never been greater. RedShiftBio recognizes this demand and is committed to providing solutions that empower researchers to accelerate the development and optimization of biopharmaceuticals.

Discover how our innovative approach to spectroscopy enables researchers to achieve high-resolution structural analysis of biomolecules with unprecedented speed and accuracy. By leveraging MMS, scientists can overcome the limitations of traditional analytical techniques, enabling deeper insights into the conformational dynamics and stability of biologics.